0.71
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SCYX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.7115
Offen:
$0.705
24-Stunden-Volumen:
77,056
Relative Volume:
0.49
Marktkapitalisierung:
$27.70M
Einnahmen:
$135.87M
Nettoeinkommen (Verlust:
$72.20M
KGV:
0.50
EPS:
1.42
Netto-Cashflow:
$45.09M
1W Leistung:
-6.58%
1M Leistung:
-3.30%
6M Leistung:
-33.02%
1J Leistung:
-66.59%
Scynexis Inc Stock (SCYX) Company Profile
Firmenname
Scynexis Inc
Sektor
Telefon
201-884-5485
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Vergleichen Sie SCYX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SCYX
Scynexis Inc
|
0.71 | 29.66M | 135.87M | 72.20M | 45.09M | 1.42 |
![]()
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-01-22 | Eingeleitet | Guggenheim | Buy |
2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-07-11 | Hochstufung | Needham | Hold → Buy |
2018-06-27 | Eingeleitet | Maxim Group | Buy |
2017-10-24 | Eingeleitet | Guggenheim | Buy |
2017-07-10 | Eingeleitet | ROTH Capital | Buy |
2017-05-09 | Herabstufung | Needham | Buy → Hold |
2017-03-03 | Bestätigt | RBC Capital Mkts | Outperform |
2016-10-20 | Eingeleitet | H.C. Wainwright | Buy |
2016-10-07 | Hochstufung | WBB Securities | Buy → Strong Buy |
2016-10-03 | Fortgesetzt | Brean Capital | Buy |
2016-08-17 | Eingeleitet | Guggenheim | Buy |
2016-08-09 | Bestätigt | Needham | Buy |
2016-08-09 | Hochstufung | WBB Securities | Speculative Buy → Buy |
2016-03-28 | Eingeleitet | Brean Capital | Buy |
2015-12-29 | Eingeleitet | WBB Securities | Speculative Buy |
2015-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
2015-06-10 | Eingeleitet | Needham | Buy |
2014-05-29 | Eingeleitet | Canaccord Genuity | Buy |
2014-05-29 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Scynexis Inc Aktie (SCYX) Neueste Nachrichten
What drives SCYNEXIS Inc. stock priceAccelerated wealth building - Autocar Professional
SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional
What analysts say about SCYNEXIS Inc. stockUnmatched profit potential - jammulinksnews.com
Is SCYNEXIS Inc. a good long term investmentRobust financial gains - jammulinksnews.com
Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News
What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser
How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser
Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com
SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Biosergen taps antifungal expert as board member - Biostock
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus
SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times
SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan
SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World
SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Scynexis: Q1 Earnings Snapshot - CT Insider
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Finanzdaten der Scynexis Inc-Aktie (SCYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):